1Q22 Business Results

Key Business Performance Remsima SC RemsimaⓇ SC prescription have been expanding since its launch in 2020, driving the growth of Infliximab market in Europe ✓ Switching from InflectraⓇ to RemsimaⓇ in EU5 regions including Germany & France, led to the increase of prescriptions of RemsimaⓇ SC M/S Trend of RemsimaⓇ & RemsimaⓇ SC in EU5 Increase of prescription of Remsima® & RemsimaⓇ SC 37% 37% 37% 35% 32% 29% 35% 34% 26% 25% 24% 28% 23% 23% 22% 19% Germany France 4% 11% 15% 22% 34% 23% 17% 15% 41% 26% 8% 66% 54% 5% 4% 37% 36% 3% 2% 1% 0% 0% 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q '19 '21 '19 '21 RemsimaⓇ RemsimaⓇ SC Note: market share is based on volume of EU5 region Source: IQVIA Inflectra® RemsimaⓇ SC Remsima' InflectraⓇ ■Remicade® + other biosimilars Note: market share is based on volume Source: IQVIA Investor Relations 2022 11

View entire presentation